MarketLens
Sign Up
Stock Analysis

Has Hims & Hers' GLP-1 Gamble Backfired Permanently

6 months ago
SHARE THIS ON:

Has Hims & Hers' GLP-1 Gamble Backfired Permanently

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Hims & Hers's GLP-1 Revenue Surge Erodes Core Profitability

Hims & Hers's GLP-1 Revenue Surge Erodes Core Profitability

2 weeks ago
Is Hims & Hers' $1.15 Billion Eucalyptus Acquisition a Game-Changer for Global Telehealth

Is Hims & Hers' $1.15 Billion Eucalyptus Acquisition a Game-Changer for Global Telehealth

6 months ago
Udine's High-Beta Bet: Navigating Volatility in Reddit and Hims & Hers

Udine's High-Beta Bet: Navigating Volatility in Reddit and Hims & Hers

4 weeks ago
Hims & Hers' Peptide Rally: A Premature Celebration of Regulatory Progress

Hims & Hers' Peptide Rally: A Premature Celebration of Regulatory Progress

1 months ago

Category

TopFeaturedPro OnlyStock AnalysisInvestment IdeasETFsCrypto

You may also like

Stock News•5 days ago

A Hims & Hers Insider Disposed of Stock as the Company Pushes Into Testosterone and Peptides. Here's What to Know

A Hims & Hers insider sold 10,201 shares worth ~$287,000 on Aug. 14, leaving 197,847 shares directly owned, as the company expands into testosterone and peptides.
HIMS
Stock News•1 week ago

Hims & Hers Health's Next Act: Making Its Own Drugs Again

Hims & Hers Health's 2Q revenue rose 38% to $753.2M, and FY outlook was raised to $3.1–$3.3B, after branded GLP-1 distribution drove growth. Gross margin fell 6 points sequentially to 64%, pressuring ...
HIMS
Stock News•3 weeks ago

Is Hims & Hers Health Stock in Trouble?

Hims & Hers Health stock fell more than 50% over the past 12 months, reflecting a sharp decline in investor confidence amid ongoing market pressures.
HIMS
Stock News•3 weeks ago

Market Matters Ep. 12: How HIMS Could Benefit From FDA Changes

Hims & Hers could gain from the FDA's impending peptide regulation decision, per DocShah Financial CEO Raul Shah. The analysis also covers UnitedHealth's outlook and broader health care sector implica...
HIMS

Breaking News

View All →
Event-Driven Investing
Shareholder Rights

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

1 week ago
Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

1 week ago
Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

1 week ago

Top Headlines

View More →
Stock News•48 minutes ago

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Stock News•49 minutes ago

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Stock News•1 hour ago

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News•1 hour ago

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Stock News•1 hour ago

Q2 Earnings Season Winds Down: 3 Companies That Broke Records